John Gillen
CEO & Director
For the past two decades John Gillen has dedicated his life to exploring the latest NAD+ (Nicotinamide Adenine Dinucleotide) therapies, delivering cutting-edge treatments to the UK and across Europe.
Learn MoreMeet the team behind our company's success! Our team consists of highly skilled professionals who are passionate about delivering exceptional results. We have diverse backgrounds and expertise in various fields, which allows us to approach problems from different perspectives.
The driving force behind our company's vision and mission
Our staff member at Eulas